SEC FORM
4
SEC Form 4
FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
OMB APPROVAL |
OMB Number: |
3235-0287 |
Estimated average burden |
hours per response: |
0.5 |
|
|
|
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b). |
1. Name and Address of Reporting Person*
C/O CLARUS VENTURES, LLC |
101 MAIN STREET, SUITE 1210 |
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC
[ GMED ]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
Director |
X |
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
3. Date of Earliest Transaction
(Month/Day/Year) 09/03/2013
|
4. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Form filed by One Reporting Person |
X |
Form filed by More than One Reporting Person |
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
1. Title of Security (Instr.
3)
|
2. Transaction Date
(Month/Day/Year) |
2A. Deemed Execution Date, if any
(Month/Day/Year) |
3. Transaction Code (Instr.
8)
|
4. Securities Acquired (A) or Disposed Of (D) (Instr.
3, 4 and 5)
|
5.
Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)
|
7. Nature of Indirect Beneficial Ownership (Instr.
4)
|
Code |
V |
Amount |
(A) or (D) |
Price |
Class A Common Stock |
09/03/2013 |
|
J
|
|
7,244,201 |
D |
$0.00
|
0 |
I |
By Fund
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivative Security (Instr.
3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Transaction Date
(Month/Day/Year) |
3A. Deemed Execution Date, if any
(Month/Day/Year) |
4. Transaction Code (Instr.
8)
|
5.
Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
3, 4 and 5)
|
6. Date Exercisable and Expiration Date
(Month/Day/Year) |
7. Title and Amount of Securities Underlying Derivative Security (Instr.
3 and 4)
|
8. Price of Derivative Security (Instr.
5)
|
9.
Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
4)
|
10. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)
|
11. Nature of Indirect Beneficial Ownership (Instr.
4)
|
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
1. Name and Address of Reporting Person*
C/O CLARUS VENTURES, LLC |
101 MAIN STREET, SUITE 1210 |
(Street)
|
1. Name and Address of Reporting Person*
C/O CLARUS VENTURES, LLC |
101 MAIN STREET, SUITE 1210 |
(Street)
|
1. Name and Address of Reporting Person*
C/O CLARUS VENTURES, LLC |
101 MAIN STREET, SUITE 1210 |
(Street)
|
1. Name and Address of Reporting Person*
C/O CLARUS VENTURES, LLC |
101 MAIN STREET, SUITE 1210 |
(Street)
|
1. Name and Address of Reporting Person*
C/O CLARUS VENTURES, LLC |
101 MAIN STREET, SUITE 1210 |
(Street)
|
1. Name and Address of Reporting Person*
C/O CLARUS VENTURES, LLC |
101 MAIN STREET, SUITE 1210 |
(Street)
|
1. Name and Address of Reporting Person*
C/O CLARUS VENTURES, LLC |
101 MAIN STREET, SUITE 1210 |
(Street)
|
1. Name and Address of Reporting Person*
C/O CLARUS VENTURES, LLC |
101 MAIN STREET, SUITE 1210 |
(Street)
|
1. Name and Address of Reporting Person*
C/O CLARUS VENTURES, LLC |
101 MAIN STREET, SUITE 1210 |
(Street)
|
Explanation of Responses: |
Remarks: |
|
/s/ Robert Liptak, Managing director of Clarus Ventures I, LLC, general partner of Clarus Ventures I Management, L.P., general partner of Clarus Lifesciences I, L.P. |
09/04/2013 |
|
Robert Liptak, Managing director of Clarus Ventures I, LLC, general partner of Clarus Ventures I Management, L.P. |
09/04/2013 |
|
Robert Liptak, Managing director of Clarus Ventures I, LLC |
09/04/2013 |
|
Robert Liptak, as attorney-in-fact for Nicholas Galakatos |
09/04/2013 |
|
Robert Liptak, as attorney-in-fact for Dennis Henner |
09/04/2013 |
|
Robert Liptak |
09/04/2013 |
|
Robert Liptak, as attorney-in-fact for Nicholas Simon |
09/04/2013 |
|
Robert Liptak, as attorney-in-fact for Michael Steinmetz |
09/04/2013 |
|
Robert Liptak, as attorney-in-fact for Kurt Wheeler |
09/04/2013 |
|
** Signature of Reporting Person |
Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* If the form is filed by more than one reporting person,
see
Instruction
4
(b)(v). |
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below
hereby
constitutes and appoints Robert Liptak with full power to act singly, his true
and lawful
attorney-in-fact, with full power of substitution, to: (i) sign any and all
instruments,
certificates and documents that may be necessary, desirable or appropriate to be
executed on
behalf of himself as an individual or in his capacity as a general partner of
any
partnership or limited liability company, pursuant to Section 13 or 16 of the
Securities
Exchange Act of 1934, as amended, and any and all regulations promulgated
thereunder, (ii)
file the same (including any amendments thereto), with all exhibits thereto, and
any other
documents in connection therewith, with the Securities and Exchange Commission,
and any
stock exchange or similar authority and (iii) take any other action of any type
whatsoever
in connection with the foregoing which, in the opinion of such attorney-in-fact,
may be of
benefit to, in the best interest of, or legally required by, the undersigned, it
being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned
pursuant to this power of attorney shall be in such form and shall contain such
terms and
conditions as such attorney-in-fact may approve in such attorney-in-fact's
discretion,
granting unto said attorney-in-fact full power and authority to do and perform
each and
every act and thing necessary, desirable or appropriate.
Each of the undersigned hereby grant to the attorney-in-fact full power and
authority to do
and perform any and every act and thing whatsoever requisite, necessary or
proper to be done
in the exercise of any of the rights and powers herein granted, as fully to all
intents and
purposes as the undersigned might or could do if personally present with full
power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact
or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause
to be done
by virtue of this power of attorney and the rights and powers herein granted.
This power of attorney shall remain in full force and effect until revoked by
the
undersigned in a signed writing delivered to the attorney-in-fact.
IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 11th day of
April,
2008.
/s/ Nicholas Galakatos
Nicholas Galakatos
/s/ Dennis Henner
Dennis Henner
/s/ Jeffrey Leiden
Jeffrey Leiden
/s/ Nick Simon
Nick Simon
/s/ Michael Steinmetz
Michael Steinmetz
/s/ Kurt Wheeler
Kurt Wheeler